Whitehawk Therapeutics (WHWK) EBIT Margin (2018 - 2025)
Historic EBIT Margin for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q1 2025 value amounting to 212.99%.
- Whitehawk Therapeutics' EBIT Margin rose 1515200.0% to 212.99% in Q1 2025 from the same period last year, while for Sep 2025 it was 754.05%, marking a year-over-year decrease of 4898900.0%. This contributed to the annual value of 259.62% for FY2024, which is 357400.0% up from last year.
- Latest data reveals that Whitehawk Therapeutics reported EBIT Margin of 212.99% as of Q1 2025, which was up 1515200.0% from 261.76% recorded in Q4 2024.
- Whitehawk Therapeutics' EBIT Margin's 5-year high stood at 113.89% during Q4 2021, with a 5-year trough of 3405.83% in Q1 2021.
- Moreover, its 5-year median value for EBIT Margin was 296.0% (2022), whereas its average is 517.45%.
- Examining YoY changes over the last 5 years, Whitehawk Therapeutics' EBIT Margin showed a top increase of 28070500bps in 2022 and a maximum decrease of -1821100bps in 2022.
- Over the past 5 years, Whitehawk Therapeutics' EBIT Margin (Quarter) stood at 113.89% in 2021, then crashed by -160bps to 296.0% in 2022, then rose by 5bps to 280.02% in 2023, then grew by 7bps to 261.76% in 2024, then grew by 19bps to 212.99% in 2025.
- Its EBIT Margin was 212.99% in Q1 2025, compared to 261.76% in Q4 2024 and 185.98% in Q3 2024.